Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05529940
Other study ID # H-2211-115-1380
Secondary ID
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date September 2023
Est. completion date December 2027

Study information

Verified date August 2023
Source Seoul National University Hospital
Contact Jin-Young Jang
Phone +82-2-2072-2194
Email jyjang4@snu.ac.kr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Rationale: Adjuvant chemotherapy after surgery significantly improved the survival of PC patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy. Neoadjuvant chemotherapy might control potential metastatic lesion which are not being detected in early diseases status and improve the R0 resection rate. In addition, it prevents futile surgery by selecting patients with rapid progression of disease. Furthermore, compared to chemotherapy administered after surgery, more patients can complete the planned chemotherapy schedule in neoadjuvant setting. Asians differ from Westerners not only in racial differences, but also in average size and body surface area. Accordingly, there is an urgent need for clinical studies on the dose, toxicity, dosing cycle, and efficacy of anticancer drugs that reflect actual clinical trials in Asian countries for Asians. There are still few studies worldwide that prospectively explored the efficacy of neoadjuvant chemotherapy in resectable PC and the administration of neoadjuvant therapy in resectable PC depends on individual clinical judgment. Therefore, systematic and prospective clinical trials are essential to standardize treatment protocol in resectable PC. Obective: To investigate whether 6 cycles of preoperative mFOLFIRINOX - surgery - 6 cycles of postoperative mFOLFIRINOX improves overall survival by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX. Study design: open-label, multicenter, randomized, phase 3 clinical trial Study population: Patients with resectable pancreatic cancer and ECOG performance 0 or 1. Intervention: Invervention arm : 6 cycles of neoadjuvant mFOLFIRINOX followed by surgical resection and 6 cycles of adjuvant mFOLFIRINOX Comparator arm : surgical resection followed by 12 cycles of adjuvant mFOLFIRINOX Primary endpoint: 2-year overall survival rate by intention-to-treat


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 609
Est. completion date December 2027
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: - A. Age: 19 to 80 years old B. Patients with a score of 0 - 2 (ECOG) when selecting a study subject C. Pancreatic ductal adenocarcinoma diagnosed by histological examination (histologic or cytopathological) D. Patients evaluated as resectable pancreatic cancer in preoperative imaging as follows (NCCN guidelines for pancreatic adenocarcinoma version 2.2021) - No arterial tumor contact (celiac asix, superior mesenteric artery, or common hepatic artery). - No tumor contact with the superior mesenteric vein or portal vein or = 180°contact without vein contour irregularity. E. No distant metastases on preoperative imaging F. Patients with adequate organ function 1. Bone marrow function: WBC 3,000/mm3 or more or ANC 1,500/mm3 or more, platelet = 100K/mm3 2. Liver function: Bilirubin = 3 x upper normal limit (=5.0 mg/dL), AST/ALT = 5 x upper normal limit (<200 IU/L) 3. Renal function (Cr clearance = 60 mL/min) or (Cr < 1.5 x upper normal limit) G. Persons physically capable of undergoing surgery H. Those who consented to the clinical trial Exclusion Criteria: - Patients who met any of the following criteria are not eligible to participate in this study. A. Those evaluated as borderline resectable or locally advanced pancreatic cancer in preoperative imaging examination B. Patients with a history of previous pancreatic surgery C. Patients with a history of previous chemotherapy or radiation therapy for pancreatic cancer D. Patients with distant metastases or recurrent pancreatic cancer E. Pancreatic body or tail cancer requiring combined resection of adjacent organs (stomach or kidney) (except for the adrenal gland) F. Patients within five years of diagnosis of other organ malignancies (with the exception of adequately treated non-melanoma skin cancer and carcinoma in situ without evidence of disease) G. Pregnant and lactating women H. Serious concomitant systemic disorders that would compromise the safety of the patient or patient's ability to complete the study at the discretion of the investigator

Study Design


Intervention

Drug:
Folfirinox
The primary aim of this trial was to investigate whether six cycles of preoperative mFOLFIRINOX followed by six cycles of postoperative mFOLFIRINOX improved the overall survival rate by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX.

Locations

Country Name City State
Korea, Republic of Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University College of Medicine Seoul
Korea, Republic of Department of Surgery, Seoul National University College of Medicine Seoul

Sponsors (5)

Lead Sponsor Collaborator
Seoul National University Hospital Gangnam Severance Hospital, Seoul National University Bundang Hospital, Seoul St. Mary's Hospital, SMG-SNU Boramae Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary 2-year survival rate The primary objective of this trial is to investigate whether 6 cycles of preoperative mFOLFIRINOX - surgery - 6 cycles of postoperative mFOLFIRINOX improves overall survival by intention-to-treat compared to surgery followed by 12 cycles of postoperative mFOLFIRINOX. 2 years
Secondary Overall survival Defined as the time from the date of randomization to the date of death from any cause. Patients who were not reported dead at the time of analysis were censored on the last day they were known to be alive. 5 years
Secondary Resection rate Referred to the proportion of patients who underwent curative resection 3 years
Secondary R0 resection rate Referred to the proportion of patients with microscopically negative resection margins due to the pathological examinations after the surgery. In this case, R0 indicated that no tumor was observed within 0 mm from the margins of resection. 3 years
Secondary Disease free survival Defined as the time between the date of randomization and the occurrence of distant metastases, locoregional progression, or death from any cause. Patients who were alive and free of these events at the last follow-up would be censored. 3 years
Secondary Recurrence rate Local recurrence is defined as recurrence in the pancreatic resection margin, residual pancreas, and regional lymph nodes, and distant metastasis is defined as recurrence in a distant organ. The local recurrence and distant metastasis rates are defined as the percentage of patients who had recurrence after the surgical resection. 3 years
Secondary Response rate in neoadjuvant setting Defined as the percentage of patients who showed complete response, partial response, and stable disease after three or six cycles of scheduled chemotherapy. The evaluation is based on RECIST v.1.1. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Active, not recruiting NCT03719833 - Sentinel Lymph Node Biopsy After Neoadjuvant Treatment in Breast Cancer Patents
Not yet recruiting NCT04384601 - Dragon III-Phase 3: Neoadjuvant Chemotherapy (FLOT Versus SOX) for Gastric Cancer Phase 3
Recruiting NCT04576143 - Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer Phase 2/Phase 3
Not yet recruiting NCT03688035 - Potential of Circulating Tumor DNA to Assess the Tumor Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
Recruiting NCT03493880 - The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments
Completed NCT06149884 - Micrometastases in Axillary Lymph Nodes in Breast Cancer, Post-neoadjuvant Chemotherapy
Recruiting NCT03715686 - To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes N/A
Recruiting NCT03750669 - Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer Phase 3
Recruiting NCT05522985 - Neoadjuvant Chemotherapytreatment of Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT03349177 - Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy Phase 2/Phase 3
Terminated NCT03585062 - Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer Phase 2
Enrolling by invitation NCT06120309 - New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
Recruiting NCT04004559 - MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis(RBC-02)
Recruiting NCT04047693 - Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma Phase 2
Recruiting NCT06220214 - Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer Early Phase 1
Recruiting NCT05910710 - Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Suspended NCT05503108 - Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer Phase 3
Recruiting NCT05367206 - Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial Phase 3
Completed NCT06151379 - Muscle Parameters and Pathological Response in Breast Cancer Patients